Olivier Bezençon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Olivier Bezençon has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
Catherine Roch
Idorsia Pharmaceuticals Ltd, Drug Discovery and Preclinical Research & Development, Hegenheimermattweg 91, Allschwil CH-4123, Switzerland
8 shared publicationsMelanie Kessler
Drug Discovery Chemistry, Biology and Pharmacology, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
7 shared publicationsThomas Pfeifer
Drug Discovery Chemistry, Biology and Pharmacology, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
7 shared publicationsRichard Moon
Drug Discovery Chemistry, Biology and Pharmacology, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
6 shared publicationsEric A. Ertel
Drug Discovery Chemistry, Biology and Pharmacology, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
5 shared publicationsJacques Mawet
Drug Discovery Chemistry, Biology and Pharmacology, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
5 shared publications
Latest Publications
- 12 August 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (16) , 17412-17426
Discovery and In-Vivo Characterization of Kv7 Channel Openers through a Phenotypic Approach
Despite the availability of approximately 30 antiseizure drugs (ASDs), epilepsy remains a major unmet clinical need, with approximately 30% of epileptic patients experiencing uncontrolled seizures despite an adequately chosen treatment. Polypharmacology is a common feature of many ASDs and polypharmacy is a usual practice to treat epileptic patients. Several approved ASDs were originally discovered through phenotypic screening in rodent models of seizures. To overcome the technical and ethical challenges associated with animal testing, we developed an in vitro assay that recapitulates seizure-related neuronal hyperexcitability phenotypes in a dish. Using this unbiased assay, a new class of urea compounds was discovered. Through optimization, compound 31 (IDOR-1104–0086) was identified as an orally bioavailable and brain-penetrant compound with in vivo efficacy in two rodent models of epilepsy and a favorable tolerability profile. Target deconvolution revealed that these ureas exert their antiseizure effects through activation of KV7 potassium channels, a mechanism consistent with the modulation of neuronal excitability.
- 12 August 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (16) , 17412-17426
Discovery and In-Vivo Characterization of Kv7 Channel Openers through a Phenotypic Approach
Despite the availability of approximately 30 antiseizure drugs (ASDs), epilepsy remains a major unmet clinical need, with approximately 30% of epileptic patients experiencing uncontrolled seizures despite an adequately chosen treatment. Polypharmacology is a common feature of many ASDs and polypharmacy is a usual practice to treat epileptic patients. Several approved ASDs were originally discovered through phenotypic screening in rodent models of seizures. To overcome the technical and ethical challenges associated with animal testing, we developed an in vitro assay that recapitulates seizure-related neuronal hyperexcitability phenotypes in a dish. Using this unbiased assay, a new class of urea compounds was discovered. Through optimization, compound 31 (IDOR-1104–0086) was identified as an orally bioavailable and brain-penetrant compound with in vivo efficacy in two rodent models of epilepsy and a favorable tolerability profile. Target deconvolution revealed that these ureas exert their antiseizure effects through activation of KV7 potassium channels, a mechanism consistent with the modulation of neuronal excitability.
- 1 December 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (23) , 5326-5331
Discovery and evaluation of Ca v 3.2-selective T-type calcium channel blockers
- 1 December 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (23) , 5326-5331
Discovery and evaluation of Ca v 3.2-selective T-type calcium channel blockers
- 20 November 2017
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 60 (23) , 9769-9789
Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies
We report here the discovery and pharmacological characterization of N-(1-benzyl-1H-pyrazol-3-yl)-2-phenylacetamide derivatives as potent, selective, brain-penetrating T-type calcium channel blockers. Optimization focused mainly on solubility, brain penetration, and the search for an aminopyrazole metabolite that would be negative in an Ames test. This resulted in the preparation and complete characterization of compound 66b (ACT-709478), which has been selected as a clinical candidate.
- 20 November 2017
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 60 (23) , 9769-9789
Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies
We report here the discovery and pharmacological characterization of N-(1-benzyl-1H-pyrazol-3-yl)-2-phenylacetamide derivatives as potent, selective, brain-penetrating T-type calcium channel blockers. Optimization focused mainly on solubility, brain penetration, and the search for an aminopyrazole metabolite that would be negative in an Ames test. This resulted in the preparation and complete characterization of compound 66b (ACT-709478), which has been selected as a clinical candidate.
- 3 October 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (23) , 5322-5325
Discovery and evaluation of Ca v 3.1-selective T-type calcium channel blockers
- 3 October 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (23) , 5322-5325
Discovery and evaluation of Ca v 3.1-selective T-type calcium channel blockers
- Open Access
- 1 October 2017
- Published by Swiss Chemical Society in Chimia
- Vol. 71 (10) , 722-729
Milestones to the Discovery of T-type Calcium Channel Blockers for the Treatment of Generalized Epilepsies
We describe the discovery and optimization of new, brain-penetrant T-type calcium channel blockers. We present optimized compounds with excellent efficacy in a rodent model of generalized absence-like epilepsy. Along the fine optimization of a chemical series with a pharmacological target located in the CNS (target potency, brain penetration, and solubility), we successfully identified an Ames negative aminopyrazole as putative metabolite of this compound series. Our efforts culminated in the selection of compound 20, which was elected as a preclinical candidate.
- 1 October 2017
- Published by Swiss Chemical Society in Chimia
- Vol. 71 (10) , 722-729
Open AccessMilestones to the Discovery of T-type Calcium Channel Blockers for the Treatment of Generalized Epilepsies
We describe the discovery and optimization of new, brain-penetrant T-type calcium channel blockers. We present optimized compounds with excellent efficacy in a rodent model of generalized absence-like epilepsy. Along the fine optimization of a chemical series with a pharmacological target located in the CNS (target potency, brain penetration, and solubility), we successfully identified an Ames negative aminopyrazole as putative metabolite of this compound series. Our efforts culminated in the selection of compound 20, which was elected as a preclinical candidate.
- Open Access
- 24 February 2017
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 60 (5) , 2163
Correction to Structure–Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel Blockers
- 24 February 2017
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 60 (5) , 2163
Open AccessCorrection to Structure–Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel Blockers
- Open Access
- 23 November 2016
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 59 (23) , 10661-10675
Structure–Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel Blockers
Despite the availability of numerous antiepileptic drugs, 20–30% of epileptic patients are pharmacoresistant with seizures not appropriately controlled. Consequently, new strategies to address this unmet medical need are required. T-type calcium channels play a key role in neuronal excitability and burst firing, and selective triple T-type calcium channel blockers could offer a new way to treat various CNS disorders, in particular epilepsy. Herein we describe the identification of new 1,4-benzodiazepines as brain penetrant and selective triple T-type calcium channel blockers. From racemic hit 4, optimization work led to the preparation of pyridodiazepine 31c with improved physicochemical properties, solubility, and metabolic stability. The racemic mixture was separated by chiral preparative HPLC, and the resulting lead compound (3R,5S)-31c showed promising efficacy in the WAG/Rij-rat model of generalized nonconvulsive absence-like epilepsy.
- 23 November 2016
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 59 (23) , 10661-10675
Open AccessStructure–Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel Blockers
Despite the availability of numerous antiepileptic drugs, 20–30% of epileptic patients are pharmacoresistant with seizures not appropriately controlled. Consequently, new strategies to address this unmet medical need are required. T-type calcium channels play a key role in neuronal excitability and burst firing, and selective triple T-type calcium channel blockers could offer a new way to treat various CNS disorders, in particular epilepsy. Herein we describe the identification of new 1,4-benzodiazepines as brain penetrant and selective triple T-type calcium channel blockers. From racemic hit 4, optimization work led to the preparation of pyridodiazepine 31c with improved physicochemical properties, solubility, and metabolic stability. The racemic mixture was separated by chiral preparative HPLC, and the resulting lead compound (3R,5S)-31c showed promising efficacy in the WAG/Rij-rat model of generalized nonconvulsive absence-like epilepsy.
- 12 September 2016
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 59 (18) , 8398-8411
Preparation, Antiepileptic Activity, and Cardiovascular Safety of Dihydropyrazoles as Brain-Penetrant T-Type Calcium Channel Blockers
A series of dihydropyrazole derivatives was developed as potent, selective, and brain-penetrating T-type calcium channel blockers. An optimized derivative, compound 6c, was advanced to in vivo studies, where it demonstrated efficacy in the WAG/Rij rat model of generalized nonconvulsive, absence-like epilepsy. Compound 6c was not efficacious in the basolateral amygdala kindling rat model of temporal lobe epilepsy, and it led to prolongation of the PR interval in ECG recordings in rodents.
- 12 September 2016
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 59 (18) , 8398-8411
Preparation, Antiepileptic Activity, and Cardiovascular Safety of Dihydropyrazoles as Brain-Penetrant T-Type Calcium Channel Blockers
A series of dihydropyrazole derivatives was developed as potent, selective, and brain-penetrating T-type calcium channel blockers. An optimized derivative, compound 6c, was advanced to in vivo studies, where it demonstrated efficacy in the WAG/Rij rat model of generalized nonconvulsive, absence-like epilepsy. Compound 6c was not efficacious in the basolateral amygdala kindling rat model of temporal lobe epilepsy, and it led to prolongation of the PR interval in ECG recordings in rodents.
- 9 April 2009
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 52 (12) , 3689-3702
Design and Preparation of Potent, Nonpeptidic, Bioavailable Renin Inhibitors
Starting from known piperidine renin inhibitors, a new series of 3,9-diazabicyclo[3.3.1]nonene derivatives was rationally designed and prepared. Optimization of the positions 3, 6, and 7 of the diazabicyclonene template led to potent renin inhibitors. The substituents attached at the positions 6 and 7 were essential for the binding affinity of these compounds for renin. The introduction of a substituent attached at the position 3 did not modify the binding affinity but allowed the modulation of the ADME properties. Our efforts led to the discovery of compound (+)-26g that inhibits renin with an IC50 of 0.20 nM in buffer and 19 nM in plasma. The pharmacokinetics properties of this and other similar compounds are discussed. Compound (+)-26g is well absorbed in rats and efficacious at 10 mg/kg in vivo.
- 9 April 2009
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 52 (12) , 3689-3702
Design and Preparation of Potent, Nonpeptidic, Bioavailable Renin Inhibitors
Starting from known piperidine renin inhibitors, a new series of 3,9-diazabicyclo[3.3.1]nonene derivatives was rationally designed and prepared. Optimization of the positions 3, 6, and 7 of the diazabicyclonene template led to potent renin inhibitors. The substituents attached at the positions 6 and 7 were essential for the binding affinity of these compounds for renin. The introduction of a substituent attached at the position 3 did not modify the binding affinity but allowed the modulation of the ADME properties. Our efforts led to the discovery of compound (+)-26g that inhibits renin with an IC50 of 0.20 nM in buffer and 19 nM in plasma. The pharmacokinetics properties of this and other similar compounds are discussed. Compound (+)-26g is well absorbed in rats and efficacious at 10 mg/kg in vivo.
- 1 August 1996
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 1996 (8) , 1259-1276
Alkylations of Chiral Imidazolidinones Derived from Di‐ and Triglycine and Attempts at Cyclisations to Give Cycloisodityrosines
Di‐ and triglycine derivatives (1–5) containing a 2‐tert‐butyl‐1,3‐imidazolidin‐4‐one moiety were prepared in rac. and enantiopure forms. By deprotonations with LiNR2 these imidazolidinones were converted to Li, Li2, and Li3 derivatives (H‐N) and the latter alkylated, preferably with the more reactive electrophiles (MeI, benzylic and allylic bromides). The diastereoselectivity at the endocyclic (imidazolidinone) position is always very high (>95:5), while it varies with respect to the newly formed stereocentres at the exocyclic positions (2:1 to >95:5). Three dozens of new di‐ and triglycine derivatives were thus prepared and fully characterised. Cyclisation attempts with seven different diaryl ethers (23, 29, 32, 35, 39, 44, 45), which are potential precursors of cycloisodityrosines, failed. The configurations of the products were assigned by X‐ray structure analysis (29, 40, 53), NMR analysis, and hydrolysis to the amino acid components, followed by GC analysis.
- 1 August 1996
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 1996 (8) , 1259-1276
Alkylations of Chiral Imidazolidinones Derived from Di‐ and Triglycine and Attempts at Cyclisations to Give Cycloisodityrosines
Di‐ and triglycine derivatives (1–5) containing a 2‐tert‐butyl‐1,3‐imidazolidin‐4‐one moiety were prepared in rac. and enantiopure forms. By deprotonations with LiNR2 these imidazolidinones were converted to Li, Li2, and Li3 derivatives (H‐N) and the latter alkylated, preferably with the more reactive electrophiles (MeI, benzylic and allylic bromides). The diastereoselectivity at the endocyclic (imidazolidinone) position is always very high (>95:5), while it varies with respect to the newly formed stereocentres at the exocyclic positions (2:1 to >95:5). Three dozens of new di‐ and triglycine derivatives were thus prepared and fully characterised. Cyclisation attempts with seven different diaryl ethers (23, 29, 32, 35, 39, 44, 45), which are potential precursors of cycloisodityrosines, failed. The configurations of the products were assigned by X‐ray structure analysis (29, 40, 53), NMR analysis, and hydrolysis to the amino acid components, followed by GC analysis.